Wigmore S J, Falconer J S, Plester C E, Ross J A, Maingay J P, Carter D C, Fearon K C
University Department of Surgery, Royal Infirmary of Edinburgh, UK.
Br J Cancer. 1995 Jul;72(1):185-8. doi: 10.1038/bjc.1995.300.
The aim of this study was to investigate the effect of the cyclo-oxygenase inhibitor ibuprofen on the acute-phase protein response and resting energy expenditure (REE) of weight-losing patients with pancreatic cancer. Patients with irresectable pancreatic cancer (n = 16) were treated with either ibuprofen (1200 mg day-1 for 7 days (n = 10) or placebo (n = 6). A group of 17 age-related non-cancer subjects were also studied. Indirect calorimetry, anthropometry, multifrequency bioelectrical impedence analysis and serum C-reactive protein (CRP) estimation were performed immediately before and after treatment. Before treatment, total REE was significantly elevated in the pancreatic cancer patients compared with healthy controls (1499 +/- 71 vs 1377 +/- 58 kcal) (P < 0.02). Following treatment the mean REE of the ibuprofen group fell significantly (1386 +/- 89 kcal) compared with pretreatment values (1468 +/- 99 kcal) (P < 0.02), whereas no change was observed in the placebo group. Serum CRP concentration was also reduced in the ibuprofen-treated group (pre-ibuprofen, 51 mg l-1; post-ibuprofen, 29 mg l-1; P < 0.05). These results suggest that ibuprofen may have a role in abrogating the catabolic processes which contribute to weight loss in patients with pancreatic cancer.
本研究的目的是调查环氧化酶抑制剂布洛芬对胰腺癌减肥患者急性期蛋白反应和静息能量消耗（REE）的影响。将无法切除胰腺癌患者（n = 16）分为布洛芬治疗组（1200 mg/天，共7天，n = 10）和安慰剂组（n = 6）。还研究了一组17名年龄相关的非癌症受试者。在治疗前后立即进行间接测热法、人体测量学、多频生物电阻抗分析和血清C反应蛋白（CRP）测定。治疗前，胰腺癌患者的总REE显著高于健康对照组（1499±71 vs 1377±58 kcal）（P < 0.02）。治疗后，布洛芬组的平均REE与治疗前值（1468±99 kcal）相比显著下降（1386±89 kcal）（P < 0.02），而安慰剂组未观察到变化。布洛芬治疗组的血清CRP浓度也降低（布洛芬治疗前，51 mg/l；布洛芬治疗后，29 mg/l；P < 0.05）。这些结果表明，布洛芬可能在消除导致胰腺癌患者体重减轻的分解代谢过程中发挥作用。
